Folgen
-
Yale oncologist Maryam Lustberg, MD, describes metastatic breast cancer, with a special focus on HR+/HER2-, which accounts for 70% of all breast cancers.
See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.
-
Dana-Farber Cancer Institute oncologist Sara Tolaney, MD, MPH, explains treatment options for HR+/HER2- metastatic breast cancer, including aromatase inhibitors and CDK4/6 inhibitors.
See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.
-
Fehlende Folgen?
-
Dr. Lustberg returns to explain how patients and oncologists work together to decide on a course of action, including what to expect from treatment and ongoing monitoring and why you have every reason to be optimistic.
See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.
-
Kristy Case, MSW, LCSW, OSW-C, discusses coping techniques—from grounding exercises to gratitude practices—that help patients stay centered.
See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.
